Deepinder Goyal is preparing for the commercial rollout of Temple, a new head-worn health monitor expected to launch with a premium price tag around ₹1 lakh. The device promises to track brain blood flow using light-based sensors, but it faces scrutiny from medical experts over its clinical validity and reliance on proprietary metrics.
Deepinder Goyal, the founder of Zomato, is moving his latest health-tech venture, Temple, from a prototype phase to a full market launch. The company is set to open pre-orders for its head-worn health monitor as early as the week of October 12, 2026. The initial rollout will prioritize users from an early-access waitlist and feature six distinct color options: True Gold, Rose Gold, Black Mirror, Real Jade, Deep Blue, and Purple Funk. While official pricing is yet to be set in stone, expectations are for a premium price point in the range of ₹75,000 to ₹1,00,000.
Proprietary Technology and Design
The Temple wearable is designed to be worn on the side of the head, a departure from the wrist-based form factor of most fitness trackers. It utilizes a technology branded as BrainFlow, which involves light-based sensing to monitor signals from vessels and tissues at the temple. The device also measures a proprietary metric called Entropy, which the company describes as a real-time index of the body’s metabolic cost, stress levels, and recovery states. Unlike standard devices, the unit is held in place by single-use adhesive attachments called Grips, which the company suggests are designed to remain secure during intense physical activity and swimming.
Clinical and Regulatory Hurdles
The product enters the market amidst significant skepticism from the medical community. Neurologists and radiologists have raised questions regarding the device’s ability to differentiate between blood flow in the scalp and actual cerebral blood flow within the brain. While the company cited a September 2026 preprint study comparing BrainFlow to established monitoring methods, this study was manufacturer-funded and remains pending peer review.
Crucially, the manufacturer has explicitly classified Temple as a consumer wellness tool rather than a certified medical diagnostic instrument. This distinction is vital for potential users, as it separates the device from clinical-grade equipment like MRI or Doppler imaging, which are currently the gold standard for neurological diagnostics.
Investor and Consumer Perspective
The primary challenge for the company will be justifying its high-end price tag in a market that is accustomed to lower-cost fitness wearables. For consumers and potential investors, the success of the product depends on balancing its novel health-tracking features against the lack of independent clinical validation. As shipments are planned for the end of 2026, market observers will be watching to see how the company manages consumer expectations, especially regarding the accuracy of its proprietary metrics. The key monitorable will be whether the brand can build trust in its data analytics while navigating the regulatory and scientific scrutiny inherent in the health-tech sector.